ΔT

Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
ACC, Gaps, Hematological Cancer Research Investment and Education Act, Patient, Click chemistry, Technology, Immunotherapy, Cell, Neoplasm, Population, ACE, 2021 Essex County Council election, Disease, Nobel Prize, Trial of the century, JITC, Tissue, B-cell lymphoma, ΔT, Journal, Society for Immunotherapy of Cancer, Society, SITC, Pharmaceutical industry, Vaccine, Chemistry, Cancer

The company will present this data at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC), being held in Boston, MA, from November 8 to 12, 2022.

Key Points: 
  • The company will present this data at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC), being held in Boston, MA, from November 8 to 12, 2022.
  • The poster presentation will showcase data demonstrating that ACE1831 is able to target cancer cells, overcome tumor defenses, and deliver a potent, cancer-killing cellular payload.
  • Details on the presentation and session information are provided below:
    The poster presentation will be accessible in person and virtually.
  • Acepodia's gamma delta T cell program harnesses the unique properties of gamma delta T cells to develop a new class of off-the-shelf cell therapies for the treatment of cancer.

Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's Lymphoma

Retrieved on: 
Monday, June 20, 2022
Cancer, Population, US Foods, ACC, FDA, Lymphocyte, Tissue, Technology, Lymphatic system, Lymphoma, NHL, Leadership, Gaps, LinkedIn, B-cell lymphoma, Disease, Clinical trial, IND, ACE, Twitter, Food, Patient, Hematological Cancer Research Investment and Education Act, Cell, ΔT, Neoplasm, Pharmaceutical industry, Vaccine

ALAMEDA, Calif. and TAIPEI, Taiwan, June 20, 2022 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today announced that it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate a Phase 1, first-in-human, multi-center clinical study of its ACE1831 in patients with non-Hodgkin's lymphoma.

Key Points: 
  • "The FDA clearance of our IND application for ACE1831 is a significant milestone for Acepodia as we move into the clinic with a first antibody armed allogeneic gamma delta T cell product candidate through our unique ACC platform.
  • Based on ACE1831's encouraging preclinical data, we believe that our antibody armed gamma delta T cell therapy has the potential to provide additional treatment options for patients with NHL," said Sonny Hsiao, Ph.D., chief executive officer of Acepodia.
  • Meanwhile, we can also significantly reduce manufacturing costs and has the potential to generate a cost-effective cancer treatment for patients.
  • Acepodia's gamma delta T cell program harnesses the unique properties of gamma delta T cells to develop a new class of allogeneic cell therapies for the treatment of cancer.

Munch's Supply, a Marcone company, Acquires Michigan-based T.A. Gentry Supply, Inc.

Retrieved on: 
Wednesday, April 20, 2022
Samsung, Ventilation, Air conditioning, Family, Microwave, General Electric, Marcone, LLC, Culture, Trane, Mitsubishi, Rheem, Kohler, SASCO, A. O. Smith, Inst, Frigidaire, L-G, Heat, Company, ΔT, HVAC, CASCO, Gentry, Partnership, Acquisition, API, American Standard, IPEX, Heating, ventilation, and air conditioning, Retail, Electrolux, Maytag, Whirlpool, Plumbing, Supply

NEW LENOX, Ill., April 20, 2022 /PRNewswire/ -- Munch's Supply (the "Company"), a leading Midwest-based heating, ventilation and air conditioning ("HVAC") distributor has acquired T.A. Gentry Supply, Inc., including its three branches servicing Lansing, Kalamazoo and Holland, Michigan. This will expand the Company's geographic footprint to 70 locations serving 17 states and one Canadian province.

Key Points: 
  • Gentry Supply, Inc., including its three branches servicing Lansing, Kalamazoo and Holland, Michigan.
  • Gentry Supply Inc. acquisition is part of our long-term strategy to expand into the plumbing segment in the Michigan market.
  • Gentry Supply Inc. name and its three locations will nicely complement our HVAC offerings in our eight Munch and Tommark locations," said Bob Munch.
  • Louis, Marcone operates 113 facilities, has approximately 2,000 employees, and serves approximately 43,000 technician customers.

Munch’s Supply Grows Canadian Presence with Acquisition of Ontario-based TML Supply

Retrieved on: 
Thursday, December 2, 2021
Interior Design, Architecture, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Trane, Rheem, API, REP, CEO, Acquisition, Company, Partnership, ΔT, Heat, Frigidaire, Mitsubishi, Air conditioning, Family, A. O. Smith, Investment, LLC, HVAC, IPEX, American Standard, Kohler, Ridgemont Equity Partners, Heating, ventilation, and air conditioning, Financial services, Munch’s Supply, Ridgemont Equity Partners, MUNCH’S SUPPLY, RIDGEMONT EQUITY PARTNERS

TML Supply President Bill Edmanson said, We are so proud of the legacy that weve built at TML Supply.

Key Points: 
  • TML Supply President Bill Edmanson said, We are so proud of the legacy that weve built at TML Supply.
  • Our customers and employees have always come first and I am excited about the bright future that a partnership with Munchs Supply offers.
  • We are excited about the opportunities this transaction provides to both TML Supply employees and customers.
  • Curtis Shea, President of Munchs Supply in Canada added, TML Supply has earned a great reputation as a preeminent provider of HVAC products in Ontario.